Skip to content

Clinical trials

Phase 1/2 Carcinoma, Non-Small-Cell Lung trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Carcinoma, Non-Small-Cell Lung Phase: Phase 1/2 Clear all

718 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20003
20014
20024
200313
200413
200510
200614
200714
200821
200912
201021
201111
201215
201310
201414
201535
201637
201743
201840
201933
202035
202152
202259
202351
202442
202545
202651

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed224
Recruiting157
Terminated129
Active, not recruiting77
Unknown status73
Withdrawn29
Not yet recruiting23
Suspended4
Enrolling by invitation2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
M.D. Anderson Cancer Center17
National Cancer Institute (NCI)17
Bristol-Myers Squibb13
Eli Lilly and Company11
Pfizer11
Memorial Sloan Kettering Cancer Center10
Novartis Pharmaceuticals9
AstraZeneca8
Genmab6
H. Lee Moffitt Cancer Center and Research Institute6

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Carcinoma, Non-Small-Cell Lung718
Lung Neoplasms158
Colorectal Neoplasms93
Melanoma91
Squamous Cell Carcinoma of Head and Neck74
Neoplasm Metastasis66
Neoplasms66
Ovarian Neoplasms62
Carcinoma, Renal Cell58
Pancreatic Neoplasms57

Trials

Showing 51 to 75 of 718. Each trial links to its page on Pharma Observatory.

618 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.